Overview
COGT market data
Price History
COGT price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.46 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.31 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -264.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $10.98 – $43.73 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $6.5B · P/B 8.49 · P/S 280.97.
Company News
Guggenheim Maintains Buy on Cogent Biosciences, Raises Price Target to $52Benzinga · Aug 12, 2026, 12:33 PM
Cogent Biosciences Files Prospectus for At-The-Market Offering Of Up To $400M In Common StockBenzinga · Aug 10, 2026, 9:27 PM
8-K filing — Cogent Biosciences, Inc. (COGT)SEC EDGAR · Aug 10, 2026, 9:19 PM
Cogent Biosciences Q2 EPS $(0.52) Beats $(0.57) EstimateBenzinga · Aug 10, 2026, 9:15 PM
Cogent Biosciences Files New Drug Application To FDA For Bezuclastinib In Advanced Systemic MastocytosisBenzinga · Jun 30, 2026, 12:10 PM
Cogent Biosciences To Present Preclinical Data From Its Novel JAK2 V617F Mutant-Selective Inhibitor At The 2026 European Hematology Association Congress, June 11-14Benzinga · Jun 12, 2026, 12:05 PM
Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price TargetBenzinga · May 29, 2026, 1:45 PM
Cogent Biosciences Says FDA Accepts NDA For Bezuclastinib In Combination With Sunitinib For Patients With GIST With PDUFA Target Action Date Of November 30Benzinga · May 28, 2026, 12:25 PM